McNeil Consumer Healthcare Responds to New Research Suggesting the Pain Reliever Acetaminophen May Reduce Risk of Hardening of the Arteries

New findings reported by Addison A. Taylor, MD, PhD, Baylor College of Medicine, Houston, at today's session of the American Heart Association in Atlanta suggest the pain reliever acetaminophen may help protect against the life-threatening condition, atherosclerosis, or hardening of the arteries. In response to these findings, McNeil Consumer Healthcare, the leading manufacturer of acetaminophen, the medicine in Tylenol, issued the following statement: "Dr. Taylor and his colleagues have now completed two studies -- one in human volunteers and one in animals -- suggesting acetaminophen at recommended doses may interfere with the early processes leading to hardening of the arteries," said Edward Nelson, MD, PhD, Vice President, Medical/Research and Development, McNeil Consumer Healthcare. "While these findings will need to be confirmed by further investigation, what we are seeing is a growing body of evidence pointing to what is potentially a very intriguing, very exciting link between acetaminophen and a possible protective effect in people at risk of cardiovascular disease," said Dr. Nelson. McNeil Consumer Healthcare, a Johnson & Johnson company, is noted for having the most extensive and comprehensive pain reliever franchise in the world. Tylenol (acetaminophen), introduced more than 40 years ago, continues to be the number one doctor- and hospital-recommended pain reliever in the country. ots Original Text Service: McNeil Consumer Healthcare Internet: Contact: Ron Schmid of McNeil Consumer Healthcare (USA) 215-273-8146

Klíčová slova PROTEXT-American Heart Association

USA, Kanada, OSN, svět a Arktida (us)


Přihlásit k odběru

Materiály označené značkou Protext nejsou součástí zpravodajského servisu ČTK a nelze je publikovat pod její značkou. Jde o komerční sdělení zadavatele, který je ve zprávě označen a který za ně nese plnou odpovědnost.